397
Views
6
CrossRef citations to date
0
Altmetric
Drug Evaluation

Current opinion on bevacizumab on endometrial cancer treatment

, MD, , MD, , MD, , MD, , MD, , MD, , MD & , MD show all

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Fabio Barra, Giulio Evangelisti, Lorenzo Ferro Desideri, Stefano Di Domenico, Domenico Ferraioli, Valerio Gaetano Vellone, Franco De Cian & Simone Ferrero. (2019) Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer. Expert Opinion on Investigational Drugs 28:2, pages 131-142.
Read now

Articles from other publishers (4)

Chong Feng, Lei Cui, Zhen Jin, Lei Sun, Xiaoyan Wang, Xinshu Chi, Qian Sun & Siyu Lian. (2022) Construction and comprehensive analysis of the competing endogenous RNA network in endometrial adenocarcinoma. BMC Genomic Data 23:1.
Crossref
Gaia Giannone, Valentina Tuninetti, Eleonora Ghisoni, Sofia Genta, Giulia Scotto, Gloria Mittica & Giorgio Valabrega. (2019) Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer. International Journal of Molecular Sciences 20:9, pages 2353.
Crossref
Tomislav Jocić & Milena Vuletić. (2018) Clinical significance of CD34 in endometrioid carcinoma of the uterine body. Materia medica 34:3, pages 1579-1586.
Crossref
Stefano Bogliolo, Barbara Gardella, Mattia Dominoni, Valentina Musacchi, Chiara Cassani, Francesca Zanellini, Annalisa De Silvestri, Chiara Roberta Gaggero, Luciana Babilonti & Arsenio Spinillo. (2015) Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma. Archives of Gynecology and Obstetrics 293:4, pages 701-708.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.